Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

AdPLA2 Blocking Peptide

  • Photo non disponible
Cat No: 10338
Antibodies - Blocking Peptides
Cayman
€141.00
Price is excluding VAT and does not include packaging neither shipping

The PLA2 superfamily consists of multiple enzymes that catalyze the hydrolysis of fatty acids from the sn-2 position in phospholipids. AdPLA2 is the first member of Group XVI phospholipases (PLA). This pH- and calcium-dependent phospholipase is highly...

More
: 200 µg

This product can only be bought through Cayman Chemical. Please contact us.

- +
Territorial Availability: Available through Bertin Pharma only in Europe
Correlated keywords:
  • HREV 107-3 PLA2GXVI HRASLS3 PLA2G16
Product Overview:
The PLA2 superfamily consists of multiple enzymes that catalyze the hydrolysis of fatty acids from the sn-2 position in phospholipids. AdPLA2 is the first member of Group XVI phospholipases (PLA). This pH- and calcium-dependent phospholipase is highly expressed in adipose tissue and is associated with adipocyte differentiation and lipolysis. It has been implicated as a major player in the development of obesity.{16809,16829} Human AdPLA2 is a 162 amino acid protein with a calculated molecular weight of 18 kDa. It contains a transmembrane region and shares 70-75% sequence similarity with the mouse and rat proteins, respectively. Cayman’s antibody was raised against the C-terminal region of the human protein.
Size 200 µg
Shipping dry ice
Stability Store at -20 degrees; shelf life 730 days
Formulation 200 µg of peptide in 200 μl TBS, pH 7.4, containing 0.1% BSA and 0.02% sodium azide
Custom Code 3504.00
UNSPSC code 12352203

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : AdPLA<sub>2</sub> Blocking Peptide There are 10 products.

Search